Microcap Ledger GRI Bio, Inc. $GRI
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- La Jolla, CA
- Fiscal year end
- December 31
- Shares outstanding
- 2,186,115 [10-Q 2026-08-14]
What the company doesAI summary of filing
GRI Bio is a clinical-stage biopharmaceutical company developing therapies that target dysregulated immune responses in inflammatory, fibrotic, and autoimmune disorders. The company's lead product candidate, GRI-0621, is an oral formulation of tazarotene (a FDA-approved topical retinoid) that inhibits type 1 invariant Natural Killer T cells for treatment of idiopathic pulmonary fibrosis and other fibrotic diseases; a Phase 2a trial in IPF patients met its primary safety endpoint and showed biomarker improvements suggesting anti-fibrotic effects. The company is pre-revenue and also developing GRI-0803, a dNKT cell activator for autoimmune disorders such as systemic lupus erythematosus, with plans to file an IND application in 2026 for Phase 1 trials. [10-K 2026-01-30]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$3.64M | −$5.13M | $10.95M | [10-Q 2026-08-14] |
| FY ended Dec 2025 | — | −$11.96M | −$10.19M | $8.23M | [10-K 2026-01-30] |
| FY ended Dec 2024 | — | −$8.21M | −$8.61M | $5.03M | [10-K 2026-01-30] |
- Quarterly cash burn
- −$2.57M
- Cash runway Estimate
- ~12.8 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-13 | 8,933,366 | [10-Q 2024-11-14] |
| 2025-03-11 | 525,358 | [10-K 2025-03-14] |
| 2025-05-14 | 2,141,473 | [10-Q 2025-05-15] |
| 2025-08-13 | 2,515,305 | [10-Q 2025-08-14] |
| 2025-11-13 | 3,268,727 | [10-Q 2025-11-14] |
| 2026-01-29 | 1,445,029 | [10-K 2026-01-30] |
| 2026-05-12 | 1,770,838 | [10-Q 2026-05-13] |
| 2026-08-13 | 2,186,115 | [10-Q 2026-08-14] |
- Shelf registration
- S-3 filed 2026-01-30; declared effective 2026-01-30 [S-3 2026-01-30]
Listing status
Current status: 3 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-01-16. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2026-01-16 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-01-16] |
| 2025-12-02 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-12-02] |
| 2025-03-11 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-03-11] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-28 | DEF 14A | Proxy statement |
| 2026-09-08 | 8-K | Regulation FD disclosure; Other events |
| 2026-08-14 | 10-Q | Quarterly report |
| 2026-08-13 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-06-18 | 8-K | Other events |
| 2026-05-14 | 8-K | Results of operations; Other events |
| 2026-05-13 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-05-13 | 10-Q | Quarterly report |
| 2026-02-13 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-02-10 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-02-04 | 8-K | Results of operations |
| 2026-01-30 | 10-K | Annual report |
Alerts for $GRI
Email me when GRI Bio, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.